Form 8-K - Current report:
SEC Accession No. 0001193125-24-080630
Filing Date
2024-03-28
Accepted
2024-03-28 16:14:07
Documents
15
Period of Report
2024-03-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d808774d8k.htm   iXBRL 8-K 35860
2 EX-10.1 d808774dex101.htm EX-10.1 212288
3 EX-99.1 d808774dex991.htm EX-99.1 9344
  Complete submission text file 0001193125-24-080630.txt   453528

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA eras-20240327.xsd EX-101.SCH 2836
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE eras-20240327_lab.xml EX-101.LAB 18738
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eras-20240327_pre.xml EX-101.PRE 11698
18 EXTRACTED XBRL INSTANCE DOCUMENT d808774d8k_htm.xml XML 3759
Mailing Address 10835 ROAD TO THE CURE, SUITE 140 SAN DIEGO CA 92121
Business Address 10835 ROAD TO THE CURE, SUITE 140 SAN DIEGO CA 92121 (858) 465-6511
Erasca, Inc. (Filer) CIK: 0001761918 (see all company filings)

EIN.: 831217027 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40602 | Film No.: 24799085
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)